非劣效-话题@MedSci - 梅斯（MedSci）

#非劣效#

21篇内容 | 1725人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1907939, encodeId=7154190e939b4, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=ESMO 2022：替雷利珠单抗作为不可切除HCC一线治疗显示出非劣效于索拉非尼的OS获益（RATIONALE 301研究）, objectType=article, longId=739072, objectId=0c76e39072d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c76e39072d5, replyNumber=0, likeNumber=75, createdTime=2023-01-08, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c76e39072d5, moduleTitle=ESMO 2022：替雷利珠单抗作为不可切除HCC一线治疗显示出非劣效于索拉非尼的OS获益（RATIONALE 301研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0c76e39072d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907938, encodeId=6d47190e938cf, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=Clin Cancer Res：中肿袁中玉教授团队SYSUCC-002研究证实HR+HER2+转移性乳腺癌患者一线曲妥珠单抗+内分泌治疗非劣效于曲妥珠单抗+化疗, objectType=article, longId=293509, objectId=872a29350972, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=872a29350972, replyNumber=0, likeNumber=88, createdTime=2022-08-03, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=872a29350972, moduleTitle=Clin Cancer Res：中肿袁中玉教授团队SYSUCC-002研究证实HR+HER2+转移性乳腺癌患者一线曲妥珠单抗+内分泌治疗非劣效于曲妥珠单抗+化疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=872a29350972)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907937, encodeId=7bb1190e937c3, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=Lancet Oncol：宫颈癌开腹手术与微创（腹腔镜）手术（LACC)后的生活质量研究：一项多中心、随机、开放标签、3期、非劣效性试验的次要结局, objectType=article, longId=217444, objectId=522c21e44426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=522c21e44426, replyNumber=0, likeNumber=102, createdTime=2022-02-24, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=522c21e44426, moduleTitle=Lancet Oncol：宫颈癌开腹手术与微创（腹腔镜）手术（LACC)后的生活质量研究：一项多中心、随机、开放标签、3期、非劣效性试验的次要结局, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=522c21e44426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907936, encodeId=0a66190e93624, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究, objectType=article, longId=214070, objectId=468d2140e0fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=468d2140e0fd, replyNumber=0, likeNumber=108, createdTime=2021-10-29, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=468d2140e0fd, moduleTitle=LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=468d2140e0fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907934, encodeId=7f32190e93496, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=Clinical Nutrition：四磨汤口服液与多潘立酮混悬液辅助螺旋型鼻肠管幽门后置管：一项多中心随机非劣效性试验, objectType=article, longId=199943, objectId=c9ea1999434e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9ea1999434e, replyNumber=0, likeNumber=86, createdTime=2020-10-30, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9ea1999434e, moduleTitle=Clinical Nutrition：四磨汤口服液与多潘立酮混悬液辅助螺旋型鼻肠管幽门后置管：一项多中心随机非劣效性试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c9ea1999434e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907935, encodeId=7328190e935f8, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=Eur Urol：前列腺手术后男性尿道压力性尿失禁手术的非劣效性随机对照试验结果（MASTER） , objectType=article, longId=207425, objectId=ebbd20e42574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebbd20e42574, replyNumber=0, likeNumber=88, createdTime=2022-01-19, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebbd20e42574, moduleTitle=Eur Urol：前列腺手术后男性尿道压力性尿失禁手术的非劣效性随机对照试验结果（MASTER） , moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ebbd20e42574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907933, encodeId=674c190e93321, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=Circulation：BioFreedom支架 vs Orsiro支架的非劣效性临床研究, objectType=article, longId=196385, objectId=25ae196385b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25ae196385b6, replyNumber=0, likeNumber=106, createdTime=2021-03-06, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25ae196385b6, moduleTitle=Circulation：BioFreedom支架 vs Orsiro支架的非劣效性临床研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=25ae196385b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907932, encodeId=eb36190e93232, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=Lancet：一种吻合性胃旁路手术与Roux-en-Y胃旁路手术治疗肥胖(YOMEGA)的疗效和安全性:一项多中心、随机、开放标签、非劣效性试验, objectType=article, longId=163537, objectId=89b716353e19, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89b716353e19, replyNumber=0, likeNumber=71, createdTime=2019-07-15, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89b716353e19, moduleTitle=Lancet：一种吻合性胃旁路手术与Roux-en-Y胃旁路手术治疗肥胖(YOMEGA)的疗效和安全性:一项多中心、随机、开放标签、非劣效性试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=89b716353e19)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907931, encodeId=2f89190e9319e, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=LANCET INFECT DIS：尼泊尔儿童10价肺炎球菌偶联疫苗两种双剂量启动方案的比较:开放标签、随机非劣效对照试验, objectType=article, longId=159413, objectId=a4a615941390, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4a615941390, replyNumber=0, likeNumber=79, createdTime=2019-08-10, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4a615941390, moduleTitle=LANCET INFECT DIS：尼泊尔儿童10价肺炎球菌偶联疫苗两种双剂量启动方案的比较:开放标签、随机非劣效对照试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a4a615941390)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907930, encodeId=96e1190e9302d, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=LANCET：支气管扩张儿童呼吸加重：阿奇霉素非劣效于阿莫西林-克拉维酸？, objectType=article, longId=152052, objectId=95451520527e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95451520527e, replyNumber=0, likeNumber=95, createdTime=2019-06-16, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95451520527e, moduleTitle=LANCET：支气管扩张儿童呼吸加重：阿奇霉素非劣效于阿莫西林-克拉维酸？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=95451520527e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907929, encodeId=a438190e9294b, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=JCO：吉非替尼vs.厄洛替尼的非劣效性研究, objectType=article, longId=65864, objectId=20536586403, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20536586403, replyNumber=0, likeNumber=82, createdTime=2016-09-05, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20536586403, moduleTitle=JCO：吉非替尼vs.厄洛替尼的非劣效性研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=20536586403)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907928, encodeId=859c190e928f7, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=The Lancet：妊娠终止的临床随访与自行评估的非劣效性试验, objectType=article, longId=42030, objectId=1c234203014, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c234203014, replyNumber=0, likeNumber=95, createdTime=2015-09-03, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c234203014, moduleTitle=The Lancet：妊娠终止的临床随访与自行评估的非劣效性试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1c234203014)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907925, encodeId=19a0190e92564, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=临床非劣效性与等效性评价的统计学方法, objectType=article, longId=31727, objectId=7f4231e2731, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f4231e2731, replyNumber=0, likeNumber=85, createdTime=2014-11-17, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f4231e2731, moduleTitle=临床非劣效性与等效性评价的统计学方法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7f4231e2731)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907923, encodeId=7b54190e923c7, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=诺和诺德降糖药Ryzodeg达非劣效性终点, objectType=article, longId=27672, objectId=0ab72e67255, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ab72e67255, replyNumber=0, likeNumber=87, createdTime=2014-01-20, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ab72e67255, moduleTitle=诺和诺德降糖药Ryzodeg达非劣效性终点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0ab72e67255)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907927, encodeId=e664190e92717, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=临床试验中采用非劣效设计应该关注的问题, objectType=article, longId=31891, objectId=221431891e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=221431891e3, replyNumber=0, likeNumber=85, createdTime=2014-07-14, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=221431891e3, moduleTitle=临床试验中采用非劣效设计应该关注的问题, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=221431891e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907924, encodeId=2dae190e9246b, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=礼来制药降糖新药Dulaglutide非劣效于利拉鲁肽（Liraglutide） (AWARD-6研究）, objectType=article, longId=31331, objectId=54b3313316b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54b3313316b, replyNumber=0, likeNumber=77, createdTime=2014-03-16, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54b3313316b, moduleTitle=礼来制药降糖新药Dulaglutide非劣效于利拉鲁肽（Liraglutide） (AWARD-6研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=54b3313316b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907926, encodeId=aeaf190e926f3, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=临床试验非劣效试验的样本量模拟计算SAS宏，以及PASS计算结果对比, objectType=article, longId=31728, objectId=c84231e2875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84231e2875, replyNumber=0, likeNumber=80, createdTime=2014-05-20, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84231e2875, moduleTitle=临床试验非劣效试验的样本量模拟计算SAS宏，以及PASS计算结果对比, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c84231e2875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907922, encodeId=2db8190e922f1, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=Pediatric Diabetes：甘精胰岛素注射液和NPH胰岛素非劣效性研究, objectType=article, longId=23609, objectId=982e2360937, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=982e2360937, replyNumber=0, likeNumber=92, createdTime=2013-12-06, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=982e2360937, moduleTitle=Pediatric Diabetes：甘精胰岛素注射液和NPH胰岛素非劣效性研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=982e2360937)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907921, encodeId=cadd190e92170, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=JAMA：HPV疫苗减量免疫方案或具非劣效性, objectType=article, longId=18405, objectId=e6ec1840592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6ec1840592, replyNumber=0, likeNumber=95, createdTime=2014-04-23, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6ec1840592, moduleTitle=JAMA：HPV疫苗减量免疫方案或具非劣效性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e6ec1840592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1907920, encodeId=a05b190e92000, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, objectTitle=非劣效、等效性、优效性相关资料汇集, objectType=article, longId=3467, objectId=7c24346ed8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c24346ed8, replyNumber=0, likeNumber=77, createdTime=2012-11-12, rootId=0, userName=tonychen21, userId=ac1c235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c24346ed8, moduleTitle=非劣效、等效性、优效性相关资料汇集, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7c24346ed8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

非劣效

2020-05-29

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

ESMO 2022：替雷利珠单抗作为不可切除HCC一线治疗显示出非劣效于索拉非尼的OS获益（RATIONALE 301研究）

2023-01-08

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

Clin Cancer Res：中肿袁中玉教授团队SYSUCC-002研究证实HR+HER2+转移性乳腺癌患者一线曲妥珠单抗+内分泌治疗非劣效于曲妥珠单抗+化疗

2022-08-03

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

Lancet Oncol：宫颈癌开腹手术与微创（腹腔镜）手术（LACC)后的生活质量研究：一项多中心、随机、开放标签、3期、非劣效性试验的次要结局

2022-02-24

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究

2021-10-29

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

Clinical Nutrition：四磨汤口服液与多潘立酮混悬液辅助螺旋型鼻肠管幽门后置管：一项多中心随机非劣效性试验

2020-10-30

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

Eur Urol：前列腺手术后男性尿道压力性尿失禁手术的非劣效性随机对照试验结果（MASTER）

2022-01-19

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

Circulation：BioFreedom支架 vs Orsiro支架的非劣效性临床研究

2021-03-06

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

Lancet：一种吻合性胃旁路手术与Roux-en-Y胃旁路手术治疗肥胖(YOMEGA)的疗效和安全性:一项多中心、随机、开放标签、非劣效性试验

2019-07-15

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

LANCET INFECT DIS：尼泊尔儿童10价肺炎球菌偶联疫苗两种双剂量启动方案的比较:开放标签、随机非劣效对照试验

2019-08-10

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

LANCET：支气管扩张儿童呼吸加重：阿奇霉素非劣效于阿莫西林-克拉维酸？

2019-06-16

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

JCO：吉非替尼vs.厄洛替尼的非劣效性研究

2016-09-05

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

The Lancet：妊娠终止的临床随访与自行评估的非劣效性试验

2015-09-03

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

临床非劣效性与等效性评价的统计学方法

2014-11-17

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

诺和诺德降糖药Ryzodeg达非劣效性终点

2014-01-20

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

临床试验中采用非劣效设计应该关注的问题

2014-07-14

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

礼来制药降糖新药Dulaglutide非劣效于利拉鲁肽（Liraglutide） (AWARD-6研究）

2014-03-16

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

临床试验非劣效试验的样本量模拟计算SAS宏，以及PASS计算结果对比

2014-05-20

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

Pediatric Diabetes：甘精胰岛素注射液和NPH胰岛素非劣效性研究

2013-12-06

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

JAMA：HPV疫苗减量免疫方案或具非劣效性

2014-04-23

tonychen21 (审核中...)

前往app查看评论内容

#非劣效#

非劣效、等效性、优效性相关资料汇集

2012-11-12

科室
- - 订阅+
  - 更多科室
工具
服务